Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Other Non-Current Liabilities (2020 - 2025)

Bolt Biotherapeutics' Other Non-Current Liabilities history spans 5 years, with the latest figure at $133000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Liabilities changed N/A year-over-year to $133000.0; the TTM value through Sep 2025 reached $133000.0, changed N/A, while the annual FY2023 figure was $43000.0, 2.38% up from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $133000.0 at Bolt Biotherapeutics, roughly flat from $133000.0 in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $321000.0 in Q1 2021 and bottomed at $42000.0 in Q4 2022.
  • The 4-year median for Other Non-Current Liabilities is $133000.0 (2025), against an average of $146466.7.
  • The largest annual shift saw Other Non-Current Liabilities tumbled 80.0% in 2022 before it rose 2.38% in 2023.
  • A 4-year view of Other Non-Current Liabilities shows it stood at $210000.0 in 2021, then crashed by 80.0% to $42000.0 in 2022, then grew by 2.38% to $43000.0 in 2023, then surged by 209.3% to $133000.0 in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Other Non-Current Liabilities are $133000.0 (Q3 2025), $133000.0 (Q2 2025), and $132000.0 (Q1 2025).